Abstract
PDE-5 inhibitors were originally studied in cardiovascular indications but were later developed and approved for on-demand treatment of erectile dysfunction (ED). A few years ago sildenafil was approved for the treatment of pulmonary hypertension, thus renewing interest in cardiovascular applications, and tadalafil became available in oncedaily formulations for erectile dysfunction management. Given the wide distribution of phosphodiesterase-5 throughout the body and its involvement in multiple functions, what can one expect in the future? To answer this we reviewed studies involving PDE-5 inhibitors that were published within the past three years and searched the US National Institutes of Health clinical trial registry for ongoing ones. PDE-5 inhibitors are being actively investigated in many disease states, with interest focusing mainly on urology and cardiovascular medicine. In urology erectile dysfunction is the primary target, followed by BPH-related lower urinary tract symptoms. As far as cardiovascular medicine is concerned, treatment of heart failure is the indication where PDE-5 inhibitors seem to be closer to clinical application but preclinical data also support a role in cardiac preconditioning.
Keywords: Phosphodiesterase-5 inhibitors, treatment, future, indications
Current Pharmaceutical Design
Title: Phosphodiesterase-5 Inhibitors: Future Perspectives
Volume: 15 Issue: 30
Author(s): Giannitsas Konstantinos and Perimenis Petros
Affiliation:
Keywords: Phosphodiesterase-5 inhibitors, treatment, future, indications
Abstract: PDE-5 inhibitors were originally studied in cardiovascular indications but were later developed and approved for on-demand treatment of erectile dysfunction (ED). A few years ago sildenafil was approved for the treatment of pulmonary hypertension, thus renewing interest in cardiovascular applications, and tadalafil became available in oncedaily formulations for erectile dysfunction management. Given the wide distribution of phosphodiesterase-5 throughout the body and its involvement in multiple functions, what can one expect in the future? To answer this we reviewed studies involving PDE-5 inhibitors that were published within the past three years and searched the US National Institutes of Health clinical trial registry for ongoing ones. PDE-5 inhibitors are being actively investigated in many disease states, with interest focusing mainly on urology and cardiovascular medicine. In urology erectile dysfunction is the primary target, followed by BPH-related lower urinary tract symptoms. As far as cardiovascular medicine is concerned, treatment of heart failure is the indication where PDE-5 inhibitors seem to be closer to clinical application but preclinical data also support a role in cardiac preconditioning.
Export Options
About this article
Cite this article as:
Konstantinos Giannitsas and Petros Perimenis, Phosphodiesterase-5 Inhibitors: Future Perspectives, Current Pharmaceutical Design 2009; 15 (30) . https://dx.doi.org/10.2174/138161209789206953
DOI https://dx.doi.org/10.2174/138161209789206953 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Plant Extracts and their Secondary Metabolites as Modulators of Kinases
Current Topics in Medicinal Chemistry Ibopamine Stimulates α-Adrenergic Receptors and D1 Dopaminergic Receptors in the Eye
Current Drug Therapy New Insights in Mast Cell Modulation by Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets Acellular Spinal Cord Scaffold Implantation Promotes Vascular Remodeling with Sustained Delivery of VEGF in a Rat Spinal Cord Hemisection Model
Current Neurovascular Research Marine-Derived Bioactive Peptides as New Anticoagulant Agents: A Review
Current Protein & Peptide Science Is there a Teratogenicity Risk Associated with Cannabis and Synthetic Cannabimimetics’ (‘Spice’) Intake?
CNS & Neurological Disorders - Drug Targets A Review of Inadequate and Excessive Weight Gain in Pregnancy
Current Women`s Health Reviews Recent Advances in Antiarrhythmic Drug Treatment of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Enhanced Proinflammatory State and Autoimmune Activation: a Breakthrough to Understanding Chronic Diseases
Current Pharmaceutical Design Combination of Captopril with Gliclazide Decreases Vascular and Renal Complications and Improves Glycemic Control in Rats with Streptozotocin- Induced Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in Health Promoting Effect of Dietary Polyphenols
Current Nutrition & Food Science Microparticles: A Pivotal Nexus in Vascular Homeostasis and Disease
Current Clinical Pharmacology Hypertension and Counter-Hypertension Mechanisms in Giraffes
Cardiovascular & Hematological Disorders-Drug Targets Heart Disease Induced by AAS Abuse, Using Experimental Mice/Rats Models and the Role of Exercise-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry CYP4 Enzymes As Potential Drug Targets: Focus on Enzyme Multiplicity, Inducers and Inhibitors, and Therapeutic Modulation of 20- Hydroxyeicosatetraenoic Acid (20-HETE) Synthase and Fatty Acid ω- Hydroxylase Activities
Current Topics in Medicinal Chemistry Acute Cerebral Blood Flow Variations after Human Cardiac Arrest Assessed by Stable Xenon Enhanced Computed Tomography
Current Neurovascular Research Editorial from Editor-in-Chief: Are Implanted Upper Airway Stimulation Devices for the Treatment of Obstructive Sleep Apnea Ready for Primetime?
Current Respiratory Medicine Reviews Analgesia and Sedation in Mechanical Ventilation in Neonatology
Current Respiratory Medicine Reviews Mixed Connective Tissue Disease (MCTD) and Undifferentiated Connective Tissue Disease (UCTD)
Current Rheumatology Reviews Contrast Medium Induced Nephropathy: New Insights into Prevention and Risk Management
Cardiovascular & Hematological Agents in Medicinal Chemistry